SNX9

Across TCGA pan-cancer cohorts, SNX9 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SNX9’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SNX9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SNX9 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where SNX9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNX9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.448	<.001	12	view →
HNSC	Female	All	−0.227	<.001	11	view →
LSCC	All	All	−0.169	<.001	7	view →
COAD	Male	All	−0.176	.002	6	view →
LUAD	All	III,IV	−0.149	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SNX9–CCRCC

Open the CCRCC breakdown →